N
AUPH icon

Natixis’s Aurinia Pharmaceuticals AUPH Stock Holding History

Natixis’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,500
Closed -$49.4K – 979
2024
Q4 		$49.4K Buy
+5,500
New +$44.9K ﹤0.01% 884
2024
Q2 		– Sell
-50,717
Closed -$254K – 1003
2024
Q1 		$254K Sell
50,717
-27,897
-35% -$189K ﹤0.01% 694
2023
Q4 		$707K Sell
78,614
-217,541
-73% -$1.79M 0.01% 576
2023
Q3 		$2.3M Buy
296,155
+33,899
+13% +$332K 0.02% 389
2023
Q2 		$2.54M Sell
262,256
-963,231
-79% -$10M 0.02% 388
2023
Q1 		$13.4M Buy
1,225,487
+250,544
+26% +$2.21M 0.12% 155
2022
Q4 		$4.21M Buy
974,943
+846,998
+662% +$4.91M 0.02% 404
2022
Q3 		$977K Sell
127,945
-872,055
-87% -$7.55M ﹤0.01% 768
2022
Q2 		$9.91M Hold
1,000,000
– – 0.04% 291
2022
Q1 		$12.4M Buy
1,000,000
+500,000
+100% +$7.73M 0.04% 367
2021
Q4 		$11.4M Buy
+500,000
New +$11.8M 0.04% 355

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Natixis's AUPH Position: Q1 2025 in Review

Natixis sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2025, closing a stake of 5,500 shares — an estimated $49.4K sold.

Natixis first reported a position in AUPH in Q4 2021 and held it in 11 quarters. The position peaked at $13.4M in Q1 2023. 214 funds tracked by Wall St. Rank hold AUPH as of Q1 2025.

  • Natixis reported no remaining Aurinia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Natixis sold 5,500 Aurinia Pharmaceuticals shares in Q1 2025, an estimated $49.4K.
  • Natixis first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 11 quarters.
  • Natixis's Aurinia Pharmaceuticals position peaked at $13.4M in Q1 2023.
  • 214 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2025.

Based on Natixis's 13F filing for Q1 2025, filed 14 May 2025.